Endocrine Abstracts (2002) 3 OC9

Breast cancer cells express the vitamin D activating enzyme 1alpha-hydroxylase

K Townsend1, KN Evans1, SV Hughes1, C Mørk Hansen2, KW Colston2, MJ Campbell1 & M Hewison1


1Division of Medical Sciences, The University of Birmingham, Queen Elizabeth Hospital, Birmingham, UK; 2Department of Oncology, Gastroenterology, Endocrinology and Metabolism, St George's Hospital Medical School, London, UK.


Studies in vitro have highlighted the potent anti-cancer effects of the active form of vitamin D, 1,25-dihydroxyvitamin D3 (1,25D3). However, the in vivo application of 1,25D3 and its synthetic analogs remains problematical due to persistent hypercalcaemic side-effects. Recent studies have shown that it may be possible to overcome this in an autocrine fashion via extra-renal synthesis of 1,25D3. In particular, analysis of prostate and colon cancer has highlighted the capacity of these tissues to generate their own 1,25D3 via expression of the enzyme 1alpha-hydroxylase. To assess the possible impact of this on breast cancer, we have characterized expression and activity of 1alpha-hydroxylase in three different breast cancer cell lines: MCF-7 (ER+ve), MCF-7/VDR (ER+ve) (Leo Pharmaceuticals) and MDA-MB-231 (MDA) (ER-ve). RT-PCR and Western blot analyses demonstrated the presence of mRNA and protein for 1alpha-hydroxylase in all three cell lines. Enzyme activity assays using 3H-25-hydroxyvitamin D3 as substrate showed similar levels of 1,25D3 synthesis in each cell line (50 fmoles/hr/mg protein). Parallel analysis of the companion enzyme 24-hydroxylase indicated that this was also expressed (approximately 100 fmoles/hr/mg protein for each line). Proliferation studies using 3H-thymidine incorporation and colony formation assays showed sensitive inhibition of cell proliferation in MCF-7 cells by 1,25D3 (70% inhibition at 10 nM for 72 hrs). In contrast both MCF-7/VDR and MDA were both completely resistant to the hormone despite showing 1,25D3-induced 24-hydroxylase assays. Data presented here highlight the capacity for local generation of active 1,25D3 within breast tumours. We postulate that this may provide a novel, 'calcium friendly' approach to the use of vitamin D in the prevention and treatment of breast cancer. However, the success of this approach will also depend on overcoming apparent vitamin D resistance in many breast cancer cell lines.

This abstract was awarded the Michael White prize

Article tools

My recent searches

No recent searches.